Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Belite Bio Inc ADR (BLTE)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/15/2025: BLTE (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
5 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $85
1 Year Target Price $85
| 3 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 30.59% | Avg. Invested days 41 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 07/15/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 2.07B USD | Price to earnings Ratio - | 1Y Target Price 85 |
Price to earnings Ratio - | 1Y Target Price 85 | ||
Volume (30-day avg) 5 | Beta -1.45 | 52 Weeks Range 43.70 - 86.53 | Updated Date 07/15/2025 |
52 Weeks Range 43.70 - 86.53 | Updated Date 07/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.36 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -22.23% | Return on Equity (TTM) -33.43% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 1924585366 | Price to Sales(TTM) - |
Enterprise Value 1924585366 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -35.61 | Shares Outstanding 32544800 | Shares Floating 14993707 |
Shares Outstanding 32544800 | Shares Floating 14993707 | ||
Percent Insiders 53.93 | Percent Institutions 0.75 |
Upturn AI SWOT
Belite Bio Inc ADR
Company Overview
History and Background
Belite Bio, Inc. (BLTE) is a biopharmaceutical company, incorporated in 2012, focuses on developing novel therapeutics targeting untreatable diseases, particularly inherited retinal diseases and metabolic diseases. It is based in Taiwan with an ADR (American Depositary Receipt) trading on the NASDAQ.
Core Business Areas
- Rare Retinal Diseases: Focuses on developing therapies for Stargardt disease and other inherited retinal diseases that currently have limited or no treatment options.
- Metabolic Diseases: Developing therapies for conditions linked to metabolic dysfunction, aiming to address underlying causes and improve patient outcomes.
Leadership and Structure
The leadership team includes key executives focused on research, development, and clinical operations. The organizational structure is typical of a biotech company, emphasizing R&D and clinical trials.
Top Products and Market Share
Key Offerings
- LBS-008 (Tinlarebant): An oral therapy in Phase 3 clinical trials for Stargardt disease. Market share is currently 0% as it's not yet approved, but potential competitors in the future gene therapy space include companies such as REGENXBIO (RGNX) and others developing gene therapies for retinal diseases. Revenues are currently $0.
Market Dynamics
Industry Overview
The biopharmaceutical industry is highly competitive and regulated, with significant investment in research and development. The rare disease market offers opportunities due to unmet needs, but also faces challenges in clinical trial recruitment and regulatory pathways.
Positioning
Belite Bio is positioned as a company specializing in rare retinal and metabolic diseases. Its competitive advantage lies in its focus on developing therapies for untreatable conditions. Its small size allows it to be nimble but can affect access to funding.
Total Addressable Market (TAM)
The TAM for Stargardt disease and other rare retinal conditions is estimated to be in the billions of dollars. Belite Bio is positioned to capture a significant portion of this market if LBS-008 is approved.
Upturn SWOT Analysis
Strengths
- Focus on underserved rare disease markets
- Promising Phase 3 clinical trial results for LBS-008
- Strong intellectual property portfolio
Weaknesses
- Reliance on a single key product (LBS-008)
- Limited revenue stream
- Small company size limits resources and capabilities
Opportunities
- Potential for accelerated regulatory approval for rare diseases
- Partnerships with larger pharmaceutical companies
- Expansion into other rare disease indications
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from larger pharmaceutical companies
- Need for additional funding
Competitors and Market Share
Key Competitors
- RGNX
- AGTC
- CRIS
- OCUL
Competitive Landscape
Belite Bio faces intense competition from larger, more established pharmaceutical companies. Its advantages lie in its focus on rare diseases and its innovative approach. However, it lacks the resources of its larger competitors.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is characterized by advancement through clinical trials.
Future Projections: Future growth is contingent on the successful commercialization of LBS-008 and potential expansion into other indications.
Recent Initiatives: Recent initiatives include progressing the Phase 3 trial for LBS-008, securing funding, and exploring strategic partnerships.
Summary
Belite Bio is a biopharmaceutical company focused on developing therapies for rare retinal and metabolic diseases. Its future depends heavily on the success of LBS-008. While the company is currently burning cash to perform R&D, it has potential for significant growth. Its main challenge is competition from larger pharmaceutical companies and funding needs.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
- ClinicalTrials.gov
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. The biopharmaceutical industry is inherently risky, and results are not guaranteed. Market share data is estimated based on industry reports and analysis.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Belite Bio Inc ADR
Exchange NASDAQ | Headquaters San Diego, CA, United States | ||
IPO Launch date 2022-04-29 | Chairman of the Board of Directors & CEO Dr. Yu-Hsin Lin M.B.A., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 25 | Website https://www.belitebio.com |
Full time employees 25 | Website https://www.belitebio.com | ||
Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. Its lead product candidate is Tinlarebant (LBS-008), an orally administered, which is in phase 3 clinical trial as an early intervention for maintaining the health and integrity of retinal tissues in stargardt disease type 1 and geographic atrophy patients. The company also develops LBS-009, an anti-retinol-binding protein 4 oral therapy, which is in preclinical development targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes, as well as gout. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc is a subsidiary of Lin Bioscience International Ltd.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.